NAUT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nautilus Biotechnology Inc (NAUT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as insider and hedge fund buying, the lack of significant revenue growth, negative financial performance, and weak technical indicators suggest caution. The stock may be worth monitoring for future developments, but it does not currently present a compelling long-term investment opportunity.
The MACD is negative and expanding (-0.0298), indicating bearish momentum. RSI is neutral at 45.641, showing no clear signal. Moving averages are converging, suggesting indecision in price direction. Key support is at 2.265, and resistance is at 2.96. The stock is trading below the pivot level of 2.613, which is a bearish sign.
Hedge funds and insiders are significantly increasing their buying activity, with hedge fund buying up 499900% and insider buying up 994.6% in recent periods. Analysts have raised the price target from $2.50 to $4, maintaining a Buy rating.
No significant news or event-driven catalysts in the past week. The stock has a 60% chance of declining by -5.27% in the next month based on similar candlestick patterns. Financial performance remains weak with no revenue growth and increasing losses.
In Q4 2025, revenue remained at $0 with no growth YoY. Net income dropped by -21.67% YoY to -$13.78 million, and EPS decreased by -21.43% YoY to -0.11. Gross margin remains at 0%. The company is not yet profitable and shows no immediate signs of financial improvement.
Guggenheim raised the price target to $4 from $2.50 and maintained a Buy rating, citing a stronger foundation and potential modest revenue in 2027. However, the revenue outlook remains distant and uncertain.
